Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...
A new technical paper titled “Hybrid tungsten oxyselenide/graphene electrodes for near-lossless 2D semiconductor phase ...
An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss while a ...
Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on ...
Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg ...
Eli Lilly stock prepares €15B Abivax acquisition as tirzepatide revenue hits $24.8B. Orforglipron oral weight loss drug ...
Free Malaysia Today on MSN
GLP-1 weight-loss drugs market 'almost like Viagra' - Pfizer CEO
Pfizer is preparing for a market for obesity drugs on par with the booming business created by erectile dysfunction drug ...
Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in ...
Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH ...
The stock market experienced volatility on Monday but closed positively, with Nifty 50 up 0.42% and Sensex up 0.36%. Market ...
Nurix Therapeutics (NRIX) stock: bexobrutideg’s BTK degradation shows strong efficacy in B-cell cancers, backed by $650M cash ...
Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback